CN102149672A - 水溶性对乙酰氨基酚类似物 - Google Patents

水溶性对乙酰氨基酚类似物 Download PDF

Info

Publication number
CN102149672A
CN102149672A CN2009801282182A CN200980128218A CN102149672A CN 102149672 A CN102149672 A CN 102149672A CN 2009801282182 A CN2009801282182 A CN 2009801282182A CN 200980128218 A CN200980128218 A CN 200980128218A CN 102149672 A CN102149672 A CN 102149672A
Authority
CN
China
Prior art keywords
acetaminophen
compound
prodrug
pain
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801282182A
Other languages
English (en)
Chinese (zh)
Inventor
N·穆罕默德
K·R·布雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeurogesX Inc
Original Assignee
NeurogesX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeurogesX Inc filed Critical NeurogesX Inc
Priority to CN201510381430.7A priority Critical patent/CN105254662A/zh
Publication of CN102149672A publication Critical patent/CN102149672A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN2009801282182A 2008-05-20 2009-05-20 水溶性对乙酰氨基酚类似物 Pending CN102149672A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510381430.7A CN105254662A (zh) 2008-05-20 2009-05-20 水溶性对乙酰氨基酚类似物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5477408P 2008-05-20 2008-05-20
US61/054,774 2008-05-20
PCT/US2009/044743 WO2009143295A1 (en) 2008-05-20 2009-05-20 Water-soluble acetaminophen analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510381430.7A Division CN105254662A (zh) 2008-05-20 2009-05-20 水溶性对乙酰氨基酚类似物

Publications (1)

Publication Number Publication Date
CN102149672A true CN102149672A (zh) 2011-08-10

Family

ID=41340538

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801282182A Pending CN102149672A (zh) 2008-05-20 2009-05-20 水溶性对乙酰氨基酚类似物
CN201510381430.7A Pending CN105254662A (zh) 2008-05-20 2009-05-20 水溶性对乙酰氨基酚类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510381430.7A Pending CN105254662A (zh) 2008-05-20 2009-05-20 水溶性对乙酰氨基酚类似物

Country Status (12)

Country Link
US (4) US20110212926A1 (https=)
EP (1) EP2291348A4 (https=)
JP (6) JP5757864B2 (https=)
KR (1) KR101698028B1 (https=)
CN (2) CN102149672A (https=)
AU (1) AU2009249067A1 (https=)
BR (1) BRPI0912326A2 (https=)
CA (1) CA2724877C (https=)
IL (1) IL209382A0 (https=)
MX (1) MX2010012648A (https=)
RU (1) RU2010151952A (https=)
WO (1) WO2009143295A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
EP2291084A4 (en) 2008-05-20 2012-04-25 Neurogesx Inc CARBONATE PRODRUGS AND METHOD FOR THEIR USE
WO2009143299A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Hepatoprotectant acetaminophen mutual prodrugs
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
WO2012137225A1 (en) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
US9024055B2 (en) 2011-09-22 2015-05-05 Acorda Therapeutics, Inc. Acetaminophen conjugates, compositions and methods of use thereof
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CN117088931A (zh) 2014-08-12 2023-11-21 莫纳什大学 定向淋巴的前药
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
RU2021103000A (ru) 2014-10-21 2021-03-01 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
US10682337B2 (en) 2015-03-03 2020-06-16 Kindred Biosciences, Inc. Compositions and methods for treatment and prevention of pyrexia in horses
US11738087B2 (en) 2015-09-08 2023-08-29 Monash University Lymph directing prodrugs
EP4295909A3 (en) * 2016-04-20 2024-07-17 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
CA3077739A1 (en) 2017-08-29 2019-03-07 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
EP3727362A4 (en) 2017-12-19 2021-10-06 PureTech LYT, Inc. MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
BR112021004199A2 (pt) 2018-09-07 2021-05-25 R.P. Scherer Technologies, Llc estabilização de formas de dosagem à base de lipídio sólido ou semissólido através da cura e da adição de tensoativo(s) de baixo teor de hlb
BR112021009353A2 (pt) 2018-11-15 2021-11-23 Abbvie Inc Formulações farmacêuticas para administração subcutânea
US11389409B2 (en) * 2019-08-30 2022-07-19 Remedy Diagnostics LLC Transdermal device comprising acetaminophen prodrug
IL295362A (en) 2020-02-05 2022-10-01 Puretech Lyt Inc Lipid drug inhibitors of neurosteroids

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322410A (en) * 1978-12-15 1982-03-30 Jacques Dugniolle P-Acetaminophenyl phosphate salts as analgesics and antipyretics
US5985856A (en) * 1997-12-31 1999-11-16 University Of Kansas Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
CN1357000A (zh) * 1998-08-07 2002-07-03 堪萨斯州立大学 位阻醇或酚的水溶性前药
WO2005077394A1 (en) * 2004-02-11 2005-08-25 Ramot At Tel-Aviv University Ltd Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK406686D0 (da) * 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5001115A (en) * 1989-05-17 1991-03-19 University Of Florida Prodrugs of biologically active hydroxyaromatic compounds
AU655762B2 (en) * 1989-12-26 1995-01-12 Nova Pharmaceutical Corporation Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US6750216B2 (en) * 1996-03-08 2004-06-15 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
IT1282736B1 (it) * 1996-05-21 1998-03-31 Angelini Ricerche Spa Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
CA2289969A1 (en) * 1997-05-15 1998-11-19 Drug Innovation & Design, Inc. Acyclovir diester derivatives
DE69912250T2 (de) * 1998-01-29 2004-07-29 Bristol-Myers Squibb Co., Wallingford Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon
DE69905380T2 (de) * 1998-09-10 2003-11-27 Nycomed Danmark A/S, Roskilde Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
JP2003528876A (ja) * 2000-03-29 2003-09-30 アルタナ ファルマ アクチエンゲゼルシャフト アルキル化されたイミダゾピリジン誘導体
JP4814486B2 (ja) * 2001-06-05 2011-11-16 シヴィダ・インコーポレイテッド 持続放出性鎮痛性化合物
PL371746A1 (en) * 2002-02-05 2005-06-27 Bristol-Myers Squibb Company N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
WO2004043493A1 (en) * 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
WO2004078180A2 (en) * 2003-03-03 2004-09-16 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating opioid tolerance
JP2006520392A (ja) * 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法
AU2003901813A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
US20050080260A1 (en) * 2003-04-22 2005-04-14 Mills Randell L. Preparation of prodrugs for selective drug delivery
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
CA2571726C (en) 2004-07-06 2013-05-21 Abbott Laboratories Prodrugs of hiv protease inhibitors
BRPI0719937A2 (pt) * 2006-12-05 2014-03-11 Neurogesx Inc Pró-fármacos e métodos de fazer e de usar os mesmos
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
EP2291084A4 (en) 2008-05-20 2012-04-25 Neurogesx Inc CARBONATE PRODRUGS AND METHOD FOR THEIR USE
WO2009143299A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Hepatoprotectant acetaminophen mutual prodrugs
US8569466B2 (en) 2008-09-10 2013-10-29 Nnochiri Ekwuribe Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers
JP2012520342A (ja) 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
US9024055B2 (en) 2011-09-22 2015-05-05 Acorda Therapeutics, Inc. Acetaminophen conjugates, compositions and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322410A (en) * 1978-12-15 1982-03-30 Jacques Dugniolle P-Acetaminophenyl phosphate salts as analgesics and antipyretics
US5985856A (en) * 1997-12-31 1999-11-16 University Of Kansas Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
CN1357000A (zh) * 1998-08-07 2002-07-03 堪萨斯州立大学 位阻醇或酚的水溶性前药
WO2005077394A1 (en) * 2004-02-11 2005-08-25 Ramot At Tel-Aviv University Ltd Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid

Also Published As

Publication number Publication date
RU2010151952A (ru) 2012-06-27
JP2020114876A (ja) 2020-07-30
JP6063072B2 (ja) 2017-01-18
JP2014111658A (ja) 2014-06-19
JP2016084359A (ja) 2016-05-19
BRPI0912326A2 (pt) 2015-10-06
US20160264605A1 (en) 2016-09-15
AU2009249067A1 (en) 2009-11-26
CA2724877C (en) 2016-09-13
US20200002364A1 (en) 2020-01-02
MX2010012648A (es) 2010-12-14
JP2018135392A (ja) 2018-08-30
CN105254662A (zh) 2016-01-20
WO2009143295A1 (en) 2009-11-26
CA2724877A1 (en) 2009-11-26
US20110212926A1 (en) 2011-09-01
EP2291348A4 (en) 2013-05-15
US9981998B2 (en) 2018-05-29
JP2017057217A (ja) 2017-03-23
JP5757864B2 (ja) 2015-08-05
IL209382A0 (en) 2011-01-31
KR101698028B1 (ko) 2017-01-26
EP2291348A1 (en) 2011-03-09
KR20110018897A (ko) 2011-02-24
JP2011520977A (ja) 2011-07-21
US20190092795A1 (en) 2019-03-28
US10442826B2 (en) 2019-10-15
US11021498B2 (en) 2021-06-01

Similar Documents

Publication Publication Date Title
US11021498B2 (en) Water-soluble acetaminophen analogs
KR101677126B1 (ko) 탄산염 프로드러그 및 그것의 사용 방법
US9096494B2 (en) Arachidonic acid analogs and methods for analgesic treatment using same
JP2021036001A (ja) 肝保護剤アセトアミノフェンミューチュアルプロドラッグ
JP2020122010A (ja) アセトアミノフェンコンジュゲートおよびその組成物ならびにその使用方法
CN100356913C (zh) 左旋(r)班布特罗及其药物用途
WO2010124522A1 (zh) 一种含砷化合物及其制备方法和用途
HK1160837A (en) Water-soluble acetaminophen analogs
WO2005016331A1 (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
JPWO2000003703A1 (ja) 新規なアレルギー疾患治療剤
HK1174895B (en) Arachidonic acid analogs and methods for analgesic treatment using same
CN108264459A (zh) 麻醉类化合物及其制备方法和在医学上的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1160837

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110810

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1160837

Country of ref document: HK